Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
1999-09-01
2002-10-22
Celsa, Bennett (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S506000, C514S617000, C514S651000, C536S103000, C540S001000, C540S145000, C540S132000, C548S500000, C564S045000
Reexamination Certificate
active
06469065
ABSTRACT:
FIELD OF THE INVENTION
The present invention describes novel nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists, and novel compositions comprising at least one nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonist, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one &agr;-adrenergic receptor antagonist, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, and overactive bladder, and methods for reversing the state of anesthesia.
BACKGROUND OF THE INVENTION
Adequate sexual function is a complex interaction of hormonal events and psychosocial relationships. There are four stages to sexual response as described in the
International Journal of Gynecology & Obstetrics,
51(3):265-277 (1995). The first stage of sexual response is desire. The second stage of sexual response is arousal. Both physical and emotional stimulation may lead to breast and genital vasodilation and clitoral engorgement (vasocongestion). In the female, dilation and engorgement of the blood vessels in the labia and tissue surrounding the vagina produce the “orgasmic platform,” an area at the distal third of the vagina where blood becomes sequestered. Localized perivaginal swelling and vaginal lubrication make up the changes in this stage of sexual response. Subsequently, ballooning of the proximal portion of the vagina and elevation of the uterus occurs. In the male, vasodilation of the cavernosal arteries and closure of the venous channels that drain the penis produce an erection. The third stage of sexual response is orgasm, while the fourth stage is resolution. Interruption or absence of any of the stages of the sexual response cycle can result in sexual dysfunction. One study found that 35% of males and 42% of females reported some form of sexual dysfunction. Read et al,
J. Public Health Med.,
19(4):387-391 (1997).
While there are obvious differences in the sexual response between males and females, one common aspect of the sexual response is the erectile response. The erectile response in both males and females is the result of engorgement of the erectile tissues of the genitalia with blood which is caused by the relaxation of smooth muscles in the arteries serving the genitalia.
In both pre-menopausal and menopausal females, sexual dysfunction can include, for example, sexual pain disorders, sexual desire disorders, sexual arousal dysfunction, orgasmic dysfunction, dyspareunia, and vaginismus. Sexual dysfunction can be caused, for example, by pregnancy, menopause, cancer, pelvic surgery, chronic medical illness or medications.
In males, some pharmacological methods of treating sexual dysfunctions are available, however, such methods have not proven to be highly satisfactory or without potentially severe side-effects. Papaverine now widely used to treat impotence, is generally effective in cases where the dysfunction is psychogenic or neurogenic and where severe atherosclerosis is not involved. Injection of papaverine, a smooth muscle relaxant, or phenoxybenzamine, a non-specific antagonist and hypotensive, into corpus cavernosum has been found to cause an erection sufficient for vaginal penetration, however, these treatments are not without the serious and often painful side effect of priapism. Also, in cases where severe atherosclerosis is not a cause of the dysfunction, intracavernosal injection of phentolamine, an &agr;-adrenergic antagonist, is used. As an alternative or, in some cases, as an adjunct to &agr;-adrenergic blockade, prostaglandin E
1
(PGE
1
) has been administered via intracavernosal injection. A major side effect frequently associated with intracorparally delivered PGE
1
is penile pain and burning.
The use of &agr;-adrenergic receptor antagonists for the treatment and prevention of benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, and overactive bladder, and for reversing the state of anesthesia has been described. For example, U.S. Pat. Nos. 5,403,847, and 5,578,611, and WO 99/25345 describe treating benign prostatic hyperplasia with specific compounds; Stanaszek et al.,
Drugs,
25(4): 339-384 (1983) reviews the use of &agr;-adrenergic receptor antagonists to treat hypertension and congestive heart failure; Goodman and Gilman, The Pharmacological Basis of Therapeutics (9th Ed.), McGraw-Hill, Inc. (1995), describe the use of &agr;-adrenergic receptor antagonists to treat variant (Printzmetal) angina and vasospastic diseases, such as Raynaud's disease; U.S. Pat. No. 4,590,202 and WO 99/07353 describe the use of adrenergic receptor antagonists in glaucoma therapy; U.S. Pat. No. 5,498,623 describes the treatment of cognitive disorders such as endogenous depression, age dependent memory impairment, and Alzheimer's disease; U.S. Pat. No. 5,281,607 describes the treatment of numerous neurodegenerative diseases, such as infantile spinal muscular atrophy, juvenile spinal muscular atrophy, hypokinetic movement disorder, Down's Syndrome in middle age, and senile dementia of Lewy body type; Sereis et al.,
Neurourol. Urodyn.,
31-36 (1998) describes the treatment of urge incontinence in women; Wein,
Urology,
43-47, (1998) describes the treatment of overactive bladder; and U.S. Pat. No. 5,635,204 discloses reversing the state of anesthesia.
There is a need in the art for new and improved treatments of sexual dysfunctions, and other diseases. The present invention is directed to these, as well as other, important ends.
SUMMARY OF THE INVENTION
Nitric oxide (NO) has been shown to mediate a number of actions, including the bactericidal and tumoricidal actions of macrophages and blood vessel relaxation of endothelial cells. NO and NO donors have also been implicated as mediators of nonvascular smooth muscle relaxation. As described herein, this effect includes the dilation of the corpus cavernous smooth muscle, an event involved in the sexual response process in both males and females. The effects of modified &agr;-adrenergic receptor antagonists which are directly or indirectly linked with a nitric oxide adduct, and which are optionally used in conjunction with NO donors, have not been previously investigated.
In arriving at the present invention it was recognized that the risk of toxicities and adverse effects that are associated with high doses of &agr;-adrenergic receptor antagonists can be avoided by the use of nitrosated and/or nitrosylated &agr;-adrenergic receptor antagonists or by the use of at least one &agr;-adrenergic receptor antagonist in combination with at least one nitric oxide donor. Such toxicities and adverse effects include postural hypotension, reflex tachycardia and other arrhythmias, syncope and, with respect to the ergot alkaloids, nausea and vomiting and, upon prolonged or excessive administration, vascular insufficiency and gangrene of the extremities. The smooth muscle relaxant properties of the &agr;-adrenergic receptor antagonists and of compounds that donate, release or transfer nitrogen monoxide or elevate levels of endogenous nitric oxide or endothelium
de Tejada Inigo Saenez
Garvey David S.
Gaston Ricky D.
Schroeder Joseph D.
Shelekhin Tatiana E.
Celsa Bennett
Hale and Dorr LLP
NitroMed Inc.
LandOfFree
Nitrosated and nitrosylated &agr;-adrenergic receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitrosated and nitrosylated &agr;-adrenergic receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitrosated and nitrosylated &agr;-adrenergic receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2960134